Sinopharm Group Co. Ltd. (SHTDY)
| Market Cap | 7.38B |
| Revenue (ttm) | 79.78B |
| Net Income (ttm) | 976.57M |
| Shares Out | n/a |
| EPS (ttm) | 0.31 |
| PE Ratio | 7.56 |
| Forward PE | n/a |
| Dividend | 0.50 (4.23%) |
| Ex-Dividend Date | Jun 18, 2024 |
| Volume | 614 |
| Average Volume | 20,894 |
| Open | 11.73 |
| Previous Close | 11.73 |
| Day's Range | 11.73 - 11.95 |
| 52-Week Range | 10.13 - 16.31 |
| Beta | 0.63 |
| RSI | 51.44 |
| Earnings Date | Apr 25, 2025 |
About Sinopharm Group
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added... [Read more]
Financial Performance
In 2024, Sinopharm Group's revenue was 584.51 billion, a decrease of -2.02% compared to the previous year's 596.57 billion. Earnings were 7.05 billion, a decrease of -22.14%.
Financial numbers in CNY Financial StatementsNews
Sinopharm Group: Mixed Read-Throughs From Peer Disclosures And Management Guidance
Sinopharm is fairly valued based on a PEG ratio of 1x. Click here to find out why I rate SHTDY stock a Hold.
Sinopharm Group: The Focus Is On Working Capital And Profitability
Sinopharm Group's earnings quality is likely to be boosted by declining days sales outstanding. Learn why SHTDF stock is a Hold.
How AI and Sinopharm’s disruptive technologies are contributing to longer human life
Over the last few years, artificial intelligence (AI) has emerged as a disruptive technology and is slowly changing almost every aspect of human life, including the healthcare sector and now, it’s als...
Pandemic Accelerates China's Drive Into mRNA Treatments
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese compan...
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine...
Diversifying Into Top-Ranked Sinopharm
There is always a bull market starting somewhere. With over-crowded U.S. indexes pushing record highs almost daily, it should be of interest to diversify into under-owned assets classes.
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm. Shanghai's S...
Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs
Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen. Sinopharm has filed fo...
6 Stocks I Just Bought For My Retirement Portfolio - Hong Kong Edition
6 Stocks I Just Bought For My Retirement Portfolio - Hong Kong Edition
Go Long On SinoPharm Group's HKEX Ticker 1099:HK
There are obvious risks investing on Chinese companies right now. President Trump is hell-bent on winning his re-election via anti-China tirades.